|
Active substance |
pirfenidone |
|
Holder |
NV Roche SA |
|
Status |
Running |
|
Indication |
treatment of patients with advanced idiopathic pulmonary fibrosis and risk of group 3 pulmonary hypertension (i.e. pulmonary hypertension occurring secondary to lung disease and/or hypoxia) and exiting study MA29957 |
|
Public documents |
|
|
Last update |
08/06/2021 |
Esbriet
Last updated on 23/03/2023